VitiligoINFLAMMAVitNCT03976622
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
An observational study of Vitiligo and Psoriasis, run by University Hospital, Bordeaux at 1 site in France.
Trial summary
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Vitiligo, Psoriasis, Alopecia Areata
- What is being tested?
- Blood samples and Skin biopsies
- How many people
- 450 participants
- Where
- 1 siteFrance
- Study dates
- 14 Jan 2020to 3 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 450 patients (300 patients with vitiligo, 50 psoriasis patients, 50 patients with atopic dermatitis, 50 patients with alopecia areata)
Who may be able to join
- Patients aged 18 to 75 years;
- Patients with non-segmental vitiligo;
- Patients with plaque psoriasis;
- Patients with atopic dermatitis;
- Patients with alopecia areata sclerosis;
- written consent, free, informed and signed by the patient and the investigator (before any examination required by the study);
- Subject affiliated or beneficiary of a social security system.
Who cannot join
- Patients with segmental vitiligo
- Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less than two weeks.
- Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks.
- Pregnant or breastfeeding women
- Patient (e) under guardianship
- Patient (e) Non-affiliated (e) a social protection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Service de Dermatologie - Hôpital Saint-André
Bordeaux, Bordeaux, 33075
About this study
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders
Read the detailed description
This study was a single-center prospective study to collect blood and skin tissue at the time of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or alopecia areata, in order to better understand and compare blood and skin immune response in chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and vitiligo.
- Conditions
- Vitiligo, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Being tested
- Blood samples, Skin biopsies
- Keywords
- Skin inflammation, Cytokines
- Medical subject headings
- Vitiligo, Psoriasis, Alopecia Areata, Dermatitis, Atopic, Dermatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood samplesBiological
Also called Blood samples: serum and PBMC
Blood samples: serum and PBMC
Skin biopsiesBiological
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
| Study group | Role | What they receive |
|---|---|---|
| vitiligo | Patients aged 18 to 75 years with non-segmental vitiligo; Receives: Biological: Blood samples; Biological: Skin biopsies | |
| psoriasis | Patients aged 18 to 75 years with plaque psoriasis; Receives: Biological: Blood samples; Biological: Skin biopsies | |
| atopic dermatitis | Patients aged 18 to 75 years with atopic dermatitis; Receives: Biological: Blood samples; Biological: Skin biopsies | |
| alopecia areata | Patients aged 18 to 75 years with alopecia areata sclerosis; Receives: Biological: Blood samples; Biological: Skin biopsies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata
Description of the phenotypic analysis of cutaneous T-cell and blood of vitiligo patients evaluated by flow cytometry
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2019
- Study start14 Jan 2020
- Primary completion3 Jun 2027 (estimated)
- Study completion3 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for VitiligoStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Julien SENESCHAL, MD, PhD, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03976622
- Sponsor's protocol ID
- CHUBX 2017/55
- Acronym
- INFLAMMAVit
- Status last verified
- May 2026
- First submitted
- 3 Jun 2019
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Jacquemin C, Taieb A, Boniface K, Seneschal J; FHU ACRONIM. Imbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo. Pigment Cell Melanoma Res. 2019 Jul;32(4):588-592. doi: 10.1111/pcmr.12763. Epub 2019 Feb 15.
PubMed 30552832
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
- ClinicalTrials.gov ID
- NCT03976622
- Acronym / sponsor ID
- INFLAMMAVit / CHUBX 2017/55
- Conditions
- Vitiligo, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Keywords
- Skin inflammation, Cytokines
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 14 Jan 2020 (actual)
- Primary completion
- 3 Jun 2027 (estimated)
- Study completion
- 3 Jun 2027 (estimated)
- First posted
- 6 Jun 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders
Detailed description
This study was a single-center prospective study to collect blood and skin tissue at the time of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or alopecia areata, in order to better understand and compare blood and skin immune response in chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and vitiligo.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| vitiligo | – | Biological: Blood samples, Biological: Skin biopsiesPatients aged 18 to 75 years with non-segmental vitiligo; |
| psoriasis | – | Biological: Blood samples, Biological: Skin biopsiesPatients aged 18 to 75 years with plaque psoriasis; |
| atopic dermatitis | – | Biological: Blood samples, Biological: Skin biopsiesPatients aged 18 to 75 years with atopic dermatitis; |
| alopecia areata | – | Biological: Blood samples, Biological: Skin biopsiesPatients aged 18 to 75 years with alopecia areata sclerosis; |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 450 patients (300 patients with vitiligo, 50 psoriasis patients, 50 patients with atopic dermatitis, 50 patients with alopecia areata)
Key inclusion criteria (7 listed)
- Patients aged 18 to 75 years;
- Patients with non-segmental vitiligo;
- Patients with plaque psoriasis;
- Patients with atopic dermatitis;
- Patients with alopecia areata sclerosis;
Key exclusion criteria (6 listed)
- Patients with segmental vitiligo
- Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less than two weeks.
- Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks.
- Pregnant or breastfeeding women
- Patient (e) under guardianship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood samplesAlso: Blood samples: serum and PBMCBlood samples: serum and PBMC | Biological | alopecia areata, atopic dermatitis, psoriasis, vitiligo |
| Skin biopsiesThese superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds. | Biological | alopecia areata, atopic dermatitis, psoriasis, vitiligo |
Primary outcome
Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata
Time frame: Day 1
Description of the phenotypic analysis of cutaneous T-cell and blood of vitiligo patients evaluated by flow cytometry
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Results publication: PubMed 30552832Jacquemin C, Taieb A, Boniface K, Seneschal J; FHU ACRONIM. Imbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo. Pigment Cell Melanoma Res. 2019 Jul;32(4):588-592. doi: 10.1111/pcmr.12763. Epub 2019 Feb 15.
- Individual participant dataSharing planned: No
Related trials for Vitiligo
RecruitingPhase 2
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
Non-Segmental Vitiligo (NSV)
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Not yet recruitingPhase 2/3
Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo
Vitiligo
RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Vitiligo, Non-Segmental Vitiligo (NSV)
Active, not recruitingPhase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Nonsegmental Vitiligo
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Julien SENESCHAL, MD, PhD principal investigator
University Hospital, Bordeaux
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vitiligo and Psoriasis, run by University Hospital, Bordeaux at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03976622, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.